Eledon Pharmaceuticals, Inc. (ELDN) Q1 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the Elladon Pharmaceuticals first quarter financial results conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded today, May 12, 2022. I would now like to turn the conference call over to Paul Little, Chief Financial Officer of Elladon. Please go ahead. Good afternoon, everyone, and thank you for joining Elladon's first quarter 2022 Operating and Financial Results Conference Call. I'm joined on today's call by David Alexander Groh, Chief Executive Officer, Steve Perrin, President and Chief Scientific Officer, and Jeff Bornstein, Chief Medical Officer. Earlier today, Elladon issued a press release announcing financial results for the first quarter ended March 31st, 2022. You may access the release under the Investors tab on our company's website at elladon.com. I would like to remind everyone that statements made during this conference call relating to Elladon's expected future performance, future business prospects, or future events or plans may include forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. All such forward-looking statements are intended to be subject to the safe harbor protection provided by the Reform Act. Actual outcomes and results could differ materially from these forecasts due to the impact of many factors beyond the control of Elladon. Elladon expressly disclaims any duty to provide updates to its forward-looking statements, whether as a result of new information, future events, or otherwise. Participants are directed to the risk factors set forth in Elladon's reports filed with the U.S. Securities and Exchange Commission. Now I would like ...